192 related articles for article (PubMed ID: 37994400)
1. Population PK/PD modeling of low-density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti-PCSK9 monoclonal antibody.
Wang EQ; Kaila N; Plowchalk D; Gibiansky L; Yunis C; Sweeney K
CPT Pharmacometrics Syst Pharmacol; 2023 Dec; 12(12):2013-2026. PubMed ID: 37994400
[TBL] [Abstract][Full Text] [Related]
2. A Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for Bococizumab, a Humanized Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, and Its Application in Early Clinical Development.
Udata C; Garzone PD; Gumbiner B; Joh T; Liang H; Liao KH; Williams JH; Meng X
J Clin Pharmacol; 2017 Jul; 57(7):855-864. PubMed ID: 28181260
[TBL] [Abstract][Full Text] [Related]
3. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.
Wan H; Gumbiner B; Joh T; Riel T; Udata C; Forgues P; Garzone PD
Clin Ther; 2017 Nov; 39(11):2243-2259.e5. PubMed ID: 29037448
[TBL] [Abstract][Full Text] [Related]
4. The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies.
Gumbiner B; Joh T; Liang H; Wan H; Levisetti M; Vana AM; Shelton DL; Forgues P; Billotte S; Pons J; Baum CM; Garzone PD
Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29078037
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics (PK) and Pharmacodynamics (PD) Analysis of LY3015014, a Monoclonal Antibody to Protein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Healthy Subjects and Hypercholesterolemia Patients.
Shen T; James DE; Krueger KA
Pharm Res; 2017 Jan; 34(1):185-192. PubMed ID: 27822850
[TBL] [Abstract][Full Text] [Related]
6. Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin.
Fazio S; Robertson DG; Joh T; Wan H; Riel T; Forgues P; Baum CM; Garzone PD; Gumbiner B
Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29057618
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive - Results From a Randomized, Placebo-Controlled, Dose-Ranging Study.
Yokote K; Kanada S; Matsuoka O; Sekino H; Imai K; Tabira J; Matsuoka N; Chaudhuri S; Teramoto T
Circ J; 2017 Sep; 81(10):1496-1505. PubMed ID: 28539539
[TBL] [Abstract][Full Text] [Related]
8. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia.
Ballantyne CM; Neutel J; Cropp A; Duggan W; Wang EQ; Plowchalk D; Sweeney K; Kaila N; Vincent J; Bays H
Am J Cardiol; 2015 May; 115(9):1212-21. PubMed ID: 25784512
[TBL] [Abstract][Full Text] [Related]
9. Bococizumab for the treatment of hypercholesterolaemia.
Ferri N; Corsini A; Sirtori CR; Ruscica M
Expert Opin Biol Ther; 2017 Feb; 17(2):237-243. PubMed ID: 28060539
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL;
J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591
[TBL] [Abstract][Full Text] [Related]
11. Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials.
Ridker PM; Amarenco P; Brunell R; Glynn RJ; Jukema JW; Kastelein JJ; Koenig W; Nissen S; Revkin J; Santos RD; Schwartz PF; Yunis C; Tardif JC;
Am Heart J; 2016 Aug; 178():135-44. PubMed ID: 27502861
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of bococizumab, a monoclonal antibody to PCSK9, after single subcutaneous injection at three sites [NCT 02043301].
Wang EQ; Plotka A; Salageanu J; Sattler C; Yunis C
Cardiovasc Ther; 2017 Oct; 35(5):. PubMed ID: 28636184
[TBL] [Abstract][Full Text] [Related]
13. Combined Semi-mechanistic Target-Mediated Drug Disposition and Pharmacokinetic-Pharmacodynamic Models of Alirocumab, PCSK9, and Low-Density Lipoprotein Cholesterol in a Pooled Analysis of Randomized Phase I/II/III Studies.
Nolain P; Djebli N; Brunet A; Fabre D; Khier S
Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):789-802. PubMed ID: 35974290
[TBL] [Abstract][Full Text] [Related]
14. Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).
Gibbs JP; Doshi S; Kuchimanchi M; Grover A; Emery MG; Dodds MG; Gibbs MA; Somaratne R; Wasserman SM; Blom D
J Clin Pharmacol; 2017 May; 57(5):616-626. PubMed ID: 27861991
[TBL] [Abstract][Full Text] [Related]
15. A Phase I Randomized Study of a Specifically Engineered, pH-Sensitive PCSK9 Inhibitor RN317 (PF-05335810) in Hypercholesterolemic Subjects on Statin Therapy.
Levisetti M; Joh T; Wan H; Liang H; Forgues P; Gumbiner B; Garzone PD
Clin Transl Sci; 2017 Jan; 10(1):3-11. PubMed ID: 27860267
[TBL] [Abstract][Full Text] [Related]
16. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
17. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab.
Ridker PM; Tardif JC; Amarenco P; Duggan W; Glynn RJ; Jukema JW; Kastelein JJP; Kim AM; Koenig W; Nissen S; Revkin J; Rose LM; Santos RD; Schwartz PF; Shear CL; Yunis C;
N Engl J Med; 2017 Apr; 376(16):1517-1526. PubMed ID: 28304227
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.
Ridker PM; Revkin J; Amarenco P; Brunell R; Curto M; Civeira F; Flather M; Glynn RJ; Gregoire J; Jukema JW; Karpov Y; Kastelein JJP; Koenig W; Lorenzatti A; Manga P; Masiukiewicz U; Miller M; Mosterd A; Murin J; Nicolau JC; Nissen S; Ponikowski P; Santos RD; Schwartz PF; Soran H; White H; Wright RS; Vrablik M; Yunis C; Shear CL; Tardif JC;
N Engl J Med; 2017 Apr; 376(16):1527-1539. PubMed ID: 28304242
[TBL] [Abstract][Full Text] [Related]
19. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
[TBL] [Abstract][Full Text] [Related]
20. Population Pharmacokinetic/Pharmacodynamic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using an Indirect Response Model to Predict Low-Density Lipoprotein Cholesterol Lowering: Support for a Biologics License Application Submission: Part II.
Nicolas X; Djebli N; Rauch C; Brunet A; Hurbin F; Martinez JM; Fabre D
Clin Pharmacokinet; 2019 Jan; 58(1):115-130. PubMed ID: 29725997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
